Prophylactic implantation of cardioverter-defibrillator in patients with advanced light-chain amyloidosis-A pilot study
- PMID: 40256665
- PMCID: PMC12009551
- DOI: 10.1002/joa3.70068
Prophylactic implantation of cardioverter-defibrillator in patients with advanced light-chain amyloidosis-A pilot study
Abstract
Background: Ventricular arrhythmias (VAs) and electromechanical dissociation have been observed as the most common causes of sudden cardiac death (SCD) in patients with light chain (AL) amyloidosis. However, an implantable cardioverter-defibrillator (ICD) has rarely been implanted in patients with advanced AL amyloidosis due to very poor prognosis.
Methods: Between July 2021 and December 2022, 10 patients with advanced cardiac AL amyloidosis referred to our institute who received prophylactic ICD implantation were prospectively recruited. The primary endpoint was the prevalence of VAs and appropriate ICD therapies determined by ICD interrogation. The secondary endpoint was all-cause mortality during the follow-up period.
Results: During a mean follow-up of 12.1 ± 4.4 months, sustained ventricular tachycardia (VT)/ventricular fibrillation (VF) occurred in 4 of 10 (40%) patients. One patient had spontaneous termination of VT before the delivery of ICD therapy, and the remaining 3 patients had ICD therapies used, either ATP or shock. Inappropriate shock was not recorded in any patients. Patients with sustained VT/VF had wider QRS duration (143 ± 41 vs. 99 ± 10 ms, p = 0.03) and a higher incidence of bundle branch block (BBB)/interventricular conduction delay (IVCD) (75% vs. 0%, p = 0.01) compared to those without.
Conclusion: VAs are commonly observed among patients with advanced AL amyloidosis, and ICD therapy can be effective in successfully treating sustained VA in these patients. On the basis of our preliminary data, prophylactic ICD implantation may be proposed to the advanced AL amyloidosis to improve the survival rate in selected patients with advanced AL amyloidosis, especially for the patients with wider QRS duration and BBB/IVCD.
Keywords: amyloidosis; implantable cardioverter‐defibrillator; survival; ventricular arrhythmia.
© 2025 The Author(s). Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of Japanese Heart Rhythm Society.
Conflict of interest statement
Authors declare no conflict of interests for this article.
Figures

Similar articles
-
Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.Ont Health Technol Assess Ser. 2005;5(14):1-74. Epub 2005 Sep 1. Ont Health Technol Assess Ser. 2005. PMID: 23074465 Free PMC article.
-
QRS Morphology and the Risk of Ventricular Tachyarrhythmia in Cardiac Resynchronization Therapy Recipients.JACC Clin Electrophysiol. 2024 Jan;10(1):16-26. doi: 10.1016/j.jacep.2023.09.018. Epub 2023 Nov 29. JACC Clin Electrophysiol. 2024. PMID: 38032575 Clinical Trial.
-
Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.Heart Rhythm. 2013 Oct;10(10):1492-8. doi: 10.1016/j.hrthm.2013.06.020. Epub 2013 Jun 26. Heart Rhythm. 2013. PMID: 23811080
-
[Long-term survival of a patient with multiple myeloma-associated severe cardiac AL amyloidosis after implantation of a cardioverter-defibrillator].Rinsho Ketsueki. 2014 Apr;55(4):450-5. Rinsho Ketsueki. 2014. PMID: 24850457 Review. Japanese.
-
Effect of ICD implantation on cardiovascular outcomes in patients with cardiac amyloidosis: A systematic review and meta-anaylsis.J Cardiovasc Electrophysiol. 2020 Jul;31(7):1749-1758. doi: 10.1111/jce.14541. Epub 2020 Jun 13. J Cardiovasc Electrophysiol. 2020. PMID: 32391952
Cited by
-
How to demonstrate the clinical implication of prophylactic implantable cardioverter-defibrillator in patients with advanced light chain amyloidosis.J Arrhythm. 2025 May 26;41(3):e70099. doi: 10.1002/joa3.70099. eCollection 2025 Jun. J Arrhythm. 2025. PMID: 40421168 Free PMC article. No abstract available.
References
-
- Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047–2060. - PubMed
-
- Sabinot A, Ghetti G, Pradelli L, Bellucci S, Lausi A, Palladini G. State‐of‐the‐art review on al amyloidosis in western countries: epidemiology, health economics, risk assessment and therapeutic management of a rare disease. Blood Rev. 2023;59:101040. - PubMed
-
- Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack FU, et al. Prophylactic implantation of cardioverter‐defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008;5:235–240. - PubMed
-
- Reisinger J, Dubrey SW, Lavalley M, Skinner M, Falk RH. Electrophysiologic abnormalities in al (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997;30:1046–1051. - PubMed
LinkOut - more resources
Full Text Sources